Stifel
SF
$67.98
-1.86%
Stifel Financial Corp. is a diversified financial services provider operating in the capital markets industry, generating revenue primarily from wealth management, investment banking, and lending. The company has transformed from a regional brokerage into a globally competitive player through strategic acquisitions, establishing a distinct identity as a mid-market investment bank and wealth manager with a strong national footprint. The current investor narrative centers on the company's resilience and performance in a challenging capital markets environment, with recent financial trends showing revenue growth but significant stock price underperformance, sparking debate about its valuation and the sustainability of its earnings momentum amid broader market volatility and interest rate uncertainty.…
SF
Stifel
$67.98
Related headlines
Investment Opinion: Should I buy SF Today?
Rating: Hold. The core thesis is that Stifel presents a compelling value proposition based on fundamentals, but significant technical and cyclical headwinds warrant caution, making it a Hold for existing investors but not yet a compelling Buy for new money. This aligns with the mixed analyst sentiment of 'Hold' and 'Market Outperform' ratings.
Supporting Evidence: The stock trades at a discounted forward P/E of 9.9x, well below typical peer multiples. It generated substantial TTM free cash flow of $993 million, supporting its 2.8% dividend. Revenue grew 11.2% YoY in Q4 2025, and net margins recovered to 15.1%. However, these positives are counterbalanced by a -19.2% 6-month price decline and trading just 2% above its 52-week low, reflecting deep pessimism.
Risks & Conditions: The two biggest risks are 1) a failure to stabilize quarterly earnings, leading to further multiple compression, and 2) a breach of the $67.96 support level triggering accelerated technical selling. This Hold would upgrade to a Buy if the stock establishes a base above support and shows consecutive quarters of stable earnings, or if the forward P/E compresses further towards 8x. It would downgrade to a Sell if revenue growth turns negative or net margins fall back below 10%. Relative to its history and sector, the stock appears fairly valued to slightly undervalued, but not deeply enough to overcome the clear negative momentum.
Sign up to view all
SF 12-Month Price Forecast
Stifel is a classic 'value trap' candidate: fundamentally sound but technically broken. The deep valuation discount and strong financials are compelling, but they are outweighed by severe negative price momentum and the cyclical uncertainty of its business model. The most likely path is a continued range-bound trade (Base Case, 60% probability) as the market requires proof of earnings stability before granting a higher multiple. The stance would upgrade to Bullish on a confirmed technical reversal above $78-82 resistance coupled with stable quarterly EPS. It would turn Bearish if support at $68 fails and QoQ revenue trends turn negative.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Stifel's 12-month outlook, with a consensus price target around $88.37 and implied upside of +30.0% versus the current price.
Average Target
$88.37
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$54 - $88
Analyst target range
Analyst coverage for Stifel is limited, with only two analysts providing estimates, indicating it is a mid-cap name with less institutional scrutiny which can lead to higher volatility and less efficient price discovery. The consensus appears neutral to cautiously optimistic, with recent institutional ratings including a mix of 'Hold', 'Market Outperform', and 'Overweight', though a notable downgrade from 'Buy' to 'Hold' by TD Cowen in January 2026 suggests some cooling sentiment. The estimated EPS range for the forward period is wide, from $7.56 to $8.18, reflecting uncertainty around the earnings trajectory, while the estimated revenue range is $7.38 billion to $7.84 billion, implying modest growth expectations from the reported $5.5 billion annual run rate.
Bulls vs Bears: SF Investment Factors
The evidence currently tilts slightly bearish due to the stock's persistent negative price momentum, severe underperformance, and the cyclical uncertainty surrounding its earnings. However, the bearish case is largely priced in, with the stock trading near 52-week lows at a discounted valuation. The most important tension in the investment debate is whether the company's strong fundamentals (healthy balance sheet, cash flow, recovering margins) can overcome the severe negative technical momentum and sector-wide headwinds. The resolution hinges on whether upcoming quarters demonstrate sustainable earnings stability, which could trigger a re-rating from its deeply oversold levels.
Bullish
- Strong Financial Health & Liquidity: The company has a robust balance sheet with a low debt-to-equity ratio of 0.36 and a strong current ratio of 5.24, indicating ample liquidity and low financial leverage. This provides significant financial flexibility for weathering downturns and pursuing strategic opportunities.
- Attractive Valuation Metrics: Stifel trades at a forward P/E of 9.9x and a trailing P/E of 13.3x, a discount to its historical range and typical capital markets peers. The forward P/E implies a 26% discount to the trailing figure, suggesting the market expects earnings growth, creating a potential valuation floor.
- Significant Free Cash Flow Generation: The company generated $993 million in free cash flow over the trailing twelve months, supporting a 2.8% dividend yield and providing capital for shareholder returns or reinvestment. This strong cash flow underpins the company's financial stability and capital allocation options.
- Revenue Growth and Margin Recovery: Q4 2025 revenue grew 11.2% YoY to $1.75 billion, with net margin improving to 15.1% from a weak Q1 2025 net margin of 3.6%. This demonstrates operational resilience and a recovery in profitability from a volatile start to the fiscal year.
Bearish
- Severe Technical Downtrend & Underperformance: The stock is in a pronounced downtrend, down -19.2% over 6 months and -25.9% YTD versus the SPY. It has underperformed the market by -17.3% over the past 3 months, reflecting persistent negative momentum and severe investor pessimism.
- Lumpy, Cyclical Earnings Performance: Quarterly revenue and earnings are highly volatile, with Q1 2025 net income of $53 million surging to Q4 2025's $264 million. This lumpiness, typical of capital markets firms, creates earnings uncertainty and makes forecasting difficult, contributing to the stock's discount.
- Limited Analyst Coverage & Downgraded Sentiment: Only two analysts cover the stock, indicating less institutional scrutiny and potential for inefficient price discovery. Sentiment has cooled, evidenced by a downgrade from 'Buy' to 'Hold' by TD Cowen in January 2026.
- High-Cost Structure Pressuring Margins: Despite a high gross margin of 89.0% in Q4 2025, the operating margin was only 17.6%, reflecting a significant cost structure. This limits operating leverage and exposes profitability to revenue volatility in its capital markets and wealth management segments.
SF Technical Analysis
The stock is in a pronounced downtrend, with a 1-year price change of only +0.73% significantly underperforming the SPY's +19.14% gain, and a 6-month decline of -19.23%. Currently trading at $69.27, the price sits just 2% above its 52-week low of $67.96, positioning it in the bottom 3% of its 52-week range ($67.96 - $89.83), which signals deep oversold conditions and potential for a value-based recovery, though it also reflects severe negative momentum and investor pessimism. Recent momentum remains weak, with the stock down -1.93% over the past month and -2.34% over the past three months, continuing the longer-term downtrend; this persistent negative performance, coupled with a relative strength reading of -17.31% over 3 months versus the SPY, indicates a lack of any meaningful bullish divergence or reversal signal. Key technical support is clearly defined at the 52-week low of $67.96, while resistance lies near the 52-week high of $89.83; a decisive break below support could trigger further selling, while a recovery above the recent local highs near $78-82 is needed to suggest a trend change. The stock's beta of 1.01 indicates market-average volatility, but its severe underperformance (-25.92% YTD vs. SPY's +6.9%) highlights significant idiosyncratic or sector-specific pressure.
Beta
1.01
1.01x market volatility
Max Drawdown
-23.5%
Largest decline past year
52-Week Range
$68-$90
Price range past year
Annual Return
-1.6%
Cumulative gain past year
| Period | SF Return | S&P 500 |
|---|---|---|
| 1m | -3.1% | -2.0% |
| 3m | -8.0% | +13.9% |
| 6m | -18.6% | +8.7% |
| 1y | -1.6% | +20.5% |
| ytd | -20.5% | +8.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SF Fundamental Analysis
Revenue growth has been positive but decelerating, with Q4 2025 revenue of $1.75 billion representing an 11.2% year-over-year increase; however, sequential quarterly revenue from Q1 to Q4 2025 shows volatility ($1.45B, $1.47B, $1.62B, $1.75B), indicating lumpy performance typical of capital markets firms. The company is profitable with a net income of $264.4 million in Q4 2025 and a net margin of 15.1%; gross margin remains robust at 89.0% for the quarter, though operating margin was 17.6%, reflecting the high-cost structure of the business, and profitability has improved significantly from a weak Q1 2025 net income of $53 million. The balance sheet is healthy with a strong current ratio of 5.24 and a conservative debt-to-equity ratio of 0.36, indicating ample liquidity and low financial leverage; the company generated substantial free cash flow of $993 million over the trailing twelve months, supporting a dividend yield of 2.8% and providing flexibility for share repurchases or strategic investments.
Quarterly Revenue
$1.8B
2025-12
Revenue YoY Growth
+0.11%
YoY Comparison
Gross Margin
+0.89%
Latest Quarter
Free Cash Flow
$993333000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SF Overvalued?
Given a positive net income, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The trailing P/E is 13.3x, while the forward P/E based on estimated EPS is 9.9x, implying the market expects earnings growth as the forward multiple is a 26% discount to the trailing figure. Compared to typical capital markets peers, Stifel's trailing P/E of 13.3x appears to be at a discount, as many larger diversified brokers and asset managers often trade in the mid-to-high teens, suggesting the market is pricing in lower growth or higher risk. Historically, the stock's own P/E ratio has fluctuated significantly, from a low around 5.8x in late 2022 to highs above 30x in early 2025; the current 13.3x sits below the multi-year average visible in the data, indicating the stock is not historically expensive and may be pricing in a cyclical trough in earnings.
PE
13.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 5x~31x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
9.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Stifel's primary financial risk is earnings volatility, as evidenced by net income swinging from $53 million in Q1 2025 to $264 million in Q4 2025. This lumpiness, driven by the cyclical nature of capital markets and investment banking fees, makes forecasting difficult and can lead to significant stock price swings around earnings. While the balance sheet is strong (D/E of 0.36), the high-cost structure, with operating margins of 17.6% lagging behind gross margins of 89.0%, indicates limited operating leverage and vulnerability to revenue downturns.
Market & Competitive Risks: The stock trades at a forward P/E of 9.9x, which is a discount to peers but also reflects market skepticism about growth sustainability. The key market risk is continued valuation compression for mid-market financials if interest rates remain elevated or capital markets activity slows further. Competitive risks are inherent as a mid-tier player competing with larger global banks for talent and deals. The stock's severe underperformance (-25.9% YTD vs. SPY) despite a market-average beta of 1.01 highlights significant sector-specific pressure that may persist.
Worst-Case Scenario: The worst-case scenario involves a sustained downturn in capital markets, leading to a sequential decline in investment banking and trading revenue, compressing margins further. This could trigger analyst downgrades and a breach of the $67.96 technical support level, leading to a momentum-driven selloff. A realistic downside could see the stock re-testing its 52-week low, implying a potential loss of approximately -2% from the current price. A more severe bear case, factoring in a deeper cyclical trough, could see a drawdown towards the -22% max drawdown level, implying a potential loss to the mid-$50s if sentiment deteriorates drastically.
FAQ
The key risks are, in order of severity: 1) Earnings Volatility Risk: Quarterly results are highly lumpy (e.g., Q1 net income of $53M vs. Q4's $264M), leading to unpredictable stock price reactions. 2) Sector/Cyclical Risk: Revenue from investment banking and wealth management is directly tied to capital markets activity and interest rates, making the business pro-cyclical. 3) Technical/Momentum Risk: The stock is in a severe downtrend, down -25.9% YTD, and a break below the $67.96 support could trigger further selling. 4) Sentiment/Liquidity Risk: Limited analyst coverage (only 2 analysts) can lead to inefficient price discovery and higher volatility.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $75 and $85, as it stabilizes with modest earnings growth meeting analyst estimates of ~$7.84 EPS. The Bull Case (25% probability) projects a rally to $85-$90 on a capital markets recovery and valuation re-rating. The Bear Case (15% probability) warns of a drop to $60-$68 if earnings disappoint and technical support fails. The Base Case is most likely, predicated on the assumption that Stifel's strong balance sheet prevents a crisis, but cyclical headwinds prevent a major rally. The average analyst revenue estimate for the forward period is ~$7.59B.
SF appears undervalued on a fundamental basis relative to its own history and sector peers. Its trailing P/E of 13.3x and forward P/E of 9.9x are at a discount to typical capital markets firms, which often trade in the mid-to-high teens. The forward P/E implies a 26% discount to trailing earnings, suggesting the market expects low growth. Compared to its own historical P/E range (from ~5.8x to over 30x), the current multiple is below average. The market is pricing in significant cyclical risk and earnings volatility, making the stock fairly valued to slightly undervalued, but not deeply so without a catalyst for improved sentiment.
SF is a potential buy only for value-oriented, patient investors comfortable with cyclicality. At a forward P/E of 9.9x and trading just 2% above its 52-week low, much of the bad news appears priced in. The 2.8% dividend and strong free cash flow provide a margin of safety. However, the severe technical downtrend (-19.2% over 6 months) and lumpy earnings create significant near-term risk. It is not a good buy for short-term traders or those seeking stable growth, but could be a good speculative buy for long-term holders betting on a capital markets recovery and valuation normalization.
SF is suitable only for a long-term investment horizon of 3-5 years. Its high earnings volatility (beta of 1.01) and sensitivity to economic cycles make it a poor short-term trading vehicle. The investment thesis is based on the company's fundamental strength and discounted valuation eventually being recognized by the market, which is a process that requires time and a potential turn in the capital markets cycle. The 2.8% dividend provides a modest income stream while waiting. Short-term traders should avoid SF due to its negative momentum and lack of near-term catalysts.